Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Salestools Logo

Salestools

The #1 AI Agent for Sales teams and Go To Market teams. Sell more, faster, with less effort.

Product

  • AI Sales Agents
  • Intent Data
  • Technology Data
  • Visitor Tracking
  • Co-Pilot
  • Social Selling

Solutions

  • Customer Service
  • E-commerce
  • SaaS
  • Enterprise
  • Small Business

Resources

  • The Report
  • Documentation
  • API Reference
  • Help Center
  • Blog
  • Case Studies
  • Webinars

Company

  • About
  • Careers
  • Press
  • Contact
  • Partners

Our locations

  • New York, HQ
  • Bucharest, AI Research Lab
  • Zug, Switzerland

Β© 2025 Salestools. All rights reserved.

Data Terms & SecurityPrivacy PolicyTerms of Service
All systems operational
Salestools LogoSalestools
Salestools AI Agents
Solutions
Resources
Company
Pricing
Back to The Report
Biotech

Forge Biologics

Forge Biologics Raises $120M Series C

$120M Series C
Total Raised
2020
Founded
200-350
Employees
Columbus, OH
Updated October 23, 2025
2 min read

Quick Facts

Valuation
Undisclosed

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Key Highlights

  • Funding Amount: $120M Series C
  • Valuation: Undisclosed
  • Headquarters: Columbus, OH
  • Founded: 2020
  • Employees: 200-350
  • Total Raised: $350M

About the Funding Round

Forge Biologics has successfully closed $120M Series C in funding, marking a significant milestone in the company's growth trajectory. This investment will enable the company to accelerate product development, expand market reach, and strengthen its position in the biotech sector.

Investor Syndicate

The round was backed by a prestigious group of investors:

  • Patient Square Capital
  • RA Capital
  • Frazier Healthcare Partners

This diverse group of investors brings not only capital but also strategic expertise and valuable networks that will help Forge Biologics achieve its ambitious goals.

Market Opportunity

The biotech market continues to experience rapid growth, driven by increasing demand for innovative solutions and digital transformation across industries. Forge Biologics's unique approach and proven technology position it well to capture significant market share in the coming years.

Company Background

Founded in 2020 and headquartered in Columbus, OH, Forge Biologics has established itself as an innovative player in the biotech space. With 200-350 employees, the company has built a strong team focused on delivering exceptional value to customers.

Next Steps

With this new funding, Forge Biologics plans to:

  • Accelerate product development and innovation
  • Expand into new markets and geographies
  • Grow the team across engineering, sales, and operations
  • Strengthen partnerships with key industry players
  • Scale infrastructure to support rapid growth

Industry Impact

This funding round represents a strong vote of confidence in Forge Biologics's vision and execution. The investment will help drive innovation in the biotech sector and create new opportunities for customers and partners.


For more information about Forge Biologics, visit their website or contact their press office.

Key Investors

Patient Square Capital
Venture Capital
Healthcare investment firm
RA Capital
Venture Capital
Healthcare investment firm
Frazier Healthcare Partners
Venture Capital
Healthcare-focused PE firm

Topics

Venture Capital(911)Series(545)BiotechFunding RoundOH

About the Author

Sarah Kim
Sarah Kim
Healthcare and biotech investment analyst with expertise in Series B+ rounds and strategic partnerships.

Related Company Reports

Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min readβ€’$251M Series B
Biotech
Vir Biotechnology

Vir Biotechnology Raises $250M

Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min readβ€’$250M
Biotech
Absci

Absci Raises $125M Series D

AI-powered drug discovery platform using deep learning and synthetic biology to design novel antibodies and biologics

David Chen
David Chen
Oct 23, 2025
0 min readβ€’$125M Series D